相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。MET Exon 14-altered Lung Cancers and MET Inhibitor Resistance
Robin Guo et al.
CLINICAL CANCER RESEARCH (2021)
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC
Gonzalo Recondo et al.
CLINICAL CANCER RESEARCH (2020)
Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
Paul K. Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
MET-dependent solid tumours - molecular diagnosis and targeted therapy
Robin Guo et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer
Juergen Wolf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations
Linda Pudelko et al.
ISCIENCE (2020)
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro
Toshio Fujino et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma
Richard Riedel et al.
LUNG CANCER (2019)
Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer
Ken Suzawa et al.
CLINICAL CANCER RESEARCH (2019)
Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib
Jin Kang et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade
Amir R. Aref et al.
LAB ON A CHIP (2018)
Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients
Dennis Plenker et al.
CLINICAL CANCER RESEARCH (2018)
MET Kinase Domain Rearrangements (KDRE) in Non-Small Cell Lung Cancer (NSCLC) Identified Through Comprehensive Genomic Profiling (CGP)
A. Schrock et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping
Sai-Hong Ignatius et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Targeting MET in Lung Cancer: Will Expectations Finally Be MET?
Alexander Drilon et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models
Lars D. Engstrom et al.
CLINICAL CANCER RESEARCH (2017)
Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer
Anna Li et al.
CLINICAL CANCER RESEARCH (2017)
Dramatic Response to Crizotinib in a Patient With Lung Cancer Positive for an HLA-DRB1-MET Gene Fusion
Kurtis D. Davies et al.
JCO PRECISION ONCOLOGY (2017)
Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping
Rebecca S. Heist et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2016)
Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
Magda Bahcall et al.
CANCER DISCOVERY (2016)
Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET plus non-small cell lung cancer (NSCLC).
Martin H. Schuler et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
Garrett M. Frampton et al.
CANCER DISCOVERY (2015)
MET Amplification Status in Therapy-Naive Adeno- and Squamous Cell Carcinomas of the Lung
Hans-Ulrich Schildhaus et al.
CLINICAL CANCER RESEARCH (2015)
The landscape of kinase fusions in cancer
Nicolas Stransky et al.
NATURE COMMUNICATIONS (2014)
Strategies for the Selective Regulation of Kinases with Allosteric Modulators: Exploiting Exclusive Structural Features
Zhizhou Fang et al.
ACS CHEMICAL BIOLOGY (2013)
A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer Patients
Ralph Tiedt et al.
CANCER RESEARCH (2011)
Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers
Ryoichi Onozato et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
分享论文
